Vertex Pharmaceuticals' SWOT analysis: stock poised for growth amid pipeline expansion
Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company with a market capitalization of $113.7 billion, is navigating a critical juncture as it seeks to expand its therapeutic reach and ...
Vertex Pharmaceuticals’ Suzetrigine: A Promising Opioid Alternative in Pain Management
Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating yesterday.Invest with ...
Vertex Pharmaceuticals' SWOT analysis: strong CF franchise fuels pipeline stock growth
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with its substantial $114.5 billion market capitalization, continues to dominate the cystic fibrosis (CF) treatment market while advancing a ...
Vertex Pharmaceuticals price target lowered to $533 from $535 at Piper Sandler
Piper Sandler lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $533 from $535 and keeps an Overweight rating on the shares ...
Morningstar6d
Vertex Pharmaceuticals Inc VRTX
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
The Motley Fool14d
Should You Buy Vertex Pharmaceuticals Stock Hand Over Fist Before Jan. 30?
Keith Speights has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Why This Beaten-Down Growth ...
ETF Daily News14d
Capital Investment Advisors LLC Cuts Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Vertex Pharmaceuticals Stock Up 3.1 % Shares of NASDAQ VRTX opened at $424.26 on Thursday. Vertex Pharmaceuticals Incorporated has a 52-week low of $377.85 and a 52-week high of $519.88. The ...
Stockhouse14d
Lost Money on Vertex Pharmaceuticals Incorporated (VRTX)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / January 15, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX ...
Wall Street Journal15d
Vertex Pharmaceuticals Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
MM&M16d
40 Under 40: Mnwabisi Mbangata, Vertex Pharmaceuticals
Mnwabisi Mbangata arrived at Vertex Pharmaceuticals almost two years ago with nearly a decade of experience — including five years at Eli Lilly in various roles — in bringing innovative therapies to ...
Seeking Alpha16d
Vertex Pharmaceuticals Incorporated (VRTX) CEO Reshma Kewalramani Hosts 43rd Annual J.P. Morgan Healthcare Conference (Transcript)
We're kicking off the 43rd Annual Healthcare Conference this morning, and I couldn't be more delighted to introduce Vertex's CEO, Reshma Kewalramani. She's going to come on stage to give a ...